Showing 2961-2970 of 5771 results for "".
- Haag-Streit to Host "Biometry Focus Month 2024" with Weekly Webinars in Novemberhttps://modernod.com/news/haag-streit-to-host-biometry-focus-month-2024-with-weekly-webinars-in-november/2482492/Haag-Streit has announced the return of "Biometry Focus Month 2024" in November. The event will feature a series of live webinars every Thursday from November 7 to November 28, 2024. Each session will address critical topics in biometry, offering cataract and refractive surgeons ke
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- Centricity Vision Unveils Enhancements to ZEPTOLink IOL Positioning System at AAO 2024https://modernod.com/news/centricity-vision-unveils-enhancements-to-zeptolink-iol-positioning-system-at-aao-2024/2482487/Centricity Vision announced platform enhancements for its ZEPTOLink IOL Positioning System designed to reduce treatment time by up to 60%. The enhancements will be highlighted at the American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21, 2024, in Chicago.
- CASExGLOBAL Launches First AI-Powered Site Management Organizationhttps://modernod.com/news/casexglobal-lauches-first-ai-powered-site-management-organization/2482484/The Centers for Advanced Surgical Exploration (CASExGLOBAL) announced a new partnership with Clinical AI and iOR Partners to introduce what it is calling the first AI-powered site management organization (SMO) and bring clinical trials to ophthalmic office-based surgery (OBS) centers. i
- FDA Approves Bausch + Lomb's enVista Envy Full Range of Vision IOLhttps://modernod.com/news/bausch-lomb-announces-fda-approval-of-envista-envy-full-range-of-vision-iol/2482482/Bausch + Lomb announced that the FDA has approved the enVista Envy full range of vision IOL. The new lens is built on the enVista IOL platform and is designed to offer patients a continuous range of vision while providing excellent tolerance for dysphotopsia.
- Ophthalmic Drug Delivery Summit to Convene in San Franciscohttps://modernod.com/news/ophthalmic-drug-delivery-summit-to-convene-in-san-francisco/2482481/In January, over 60 world-leading specialists in ophthalmic drug delivery will gather in San Francisco for the 3rd annual Ophthalmic Drug Delivery Summit, an industry-focused event dedicated to enhancing the effectiveness, durability, and minimally invasive nature of retinal drug delivery.</
- Beyeonics Vision Launches Beyeonics One Featuring Infrared Technologyhttps://modernod.com/news/beyeonics-vision-launches-beyeonics-one-featuring-infrared-technology/2482478/Beyeonics Vision announced the launch of Beyeonics One with invisible light based on infrared night-vision technology. Beyeonics One integrates infrared illumination to optimize visualization, improving surgical outcomes and enhancing patient comfort. Accor
- Nanoscope Therapeutics Plans to Submit BLA for Gene Therapy to Treat RPhttps://modernod.com/news/nanoscope-therapeutics-plans-to-submit-bla-for-gene-therapy-to-treat-retinitis-pigmentosa/2482476/Nanoscope Therapeutics has announced a successful meeting with the FDA regarding its lead clinical program, MCO-010, for the treatment of retinitis pigmentosa (RP). Following regulatory feedback from the FDA, the company plans to initiate a rolling submission of its biologics license ap
- Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMDhttps://modernod.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/Clearside Biomedical announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints. In the trial, patients treated with suprachoroidal CLS-AX show
- Orasis Secures $78 Million to Support Commercial Launch of Presbyopia Eye Drop Qlosihttps://modernod.com/news/orasis-secures-78-million-to-support-commercial-launch-of-presbyopia-eye-drops-qlosi/2482474/Orasis Pharmaceuticals announced the completion of a $78 million Series D financing round to support the commercial launch of its presbyopia eye drop, Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%. The funding round includes a $68 million equity investment&nb